Hong Kong Stock Movement: DIAGENS-B falls 16.35%, inclusion in the Hang Seng Index fails to stop selling pressure?

Hong Kong Stock Movement

DIAGENS-B fell 16.35%. Based on recent key news:

On August 24, DIAGENS-B was included in the Hang Seng Index constituents, including the Hang Seng Composite Index and the Hang Seng Biotechnology Index. This move signifies that the company meets the trading standards for Stock Connect, and the market recognizes its long-term growth potential. However, the stock price experienced a significant decline, possibly related to concerns about short-term valuations being too high. Source: Zhitong Finance
On August 24, DIAGENS-B surged over 22% in early trading, reaching a new high since its listing, before retreating. Despite being included in multiple Hang Seng indices, the market acknowledges its AI technology strength, but the stock price remains volatile, indicating unstable investor sentiment. Source: Zhitong Finance
On August 24, DIAGENS-B, as a rare target in the AI4S field, attracted demand for allocation from southbound funds. However, despite the potential to enhance liquidity and trading activity, the stock price still fell sharply, reflecting market divergence on its valuation. Source: Zhitong Finance. The AI medical field is gaining attention, with active capital flow.

Stocks with High Trading Volume in the Industry

MicroPort Scientific Corporation-B rose 2.42%. Based on recent key news:

On August 25, MicroPort Scientific Corporation-B released its latest financial report, showing a significant improvement in profitability. The company reported a 15% increase in core business revenue, which boosted market confidence in its future development and drove the stock price up.
On August 24, MicroPort Scientific Corporation-B announced a cooperation agreement with a large hospital to jointly develop new medical robot technology. This news was interpreted by the market as a significant advancement in the company's technological innovation, further boosting the stock price.
On August 23, analysts generally raised the target price for MicroPort Scientific Corporation-B, expecting its future performance to continue growing. Analysts believe the company's leading position in the medical robotics field will bring more market share, driving the stock price up. The medical robotics industry has a broad outlook, with noticeable capital inflow.

Tianxing Medical rose 0.87%. Based on recent key news:

On August 24, Tianxing Medical announced that it would be included in the Hang Seng Composite Index constituents, effective from September 7. Following this announcement, the company's stock price rose 0.87%, with a trading volume of HKD 25.45 million. Source: Zhitong Finance
On August 24, Hang Seng Indexes Company announced the results of the review of the Hang Seng Index series for the second quarter of 2026, with Tianxing Medical selected for inclusion in the Hang Seng Composite Index constituents. This move is expected to make the company's shares meet the inclusion standards for Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, further enhancing the company's visibility and investability in the Hong Kong capital market. Source: Economic Information Daily
On August 24, Tianxing Medical issued a statement indicating that being included in the Hang Seng Composite Index is an important progress in the company's capital market development since its listing, expected to expand the coverage of potential investors. The company will continue to focus on product innovation in the field of sports medicine, creating clinical value, and developing global business, continuously improving operational quality. Source: Zhitong Finance. The announcement of the Hang Seng Index series review results has increased market attention Ai Kang Medical fell 7.07%. Based on recent key news:
On August 27, Ai Kang Medical announced its interim results, with a revenue growth of 10.2%, but the stock price fell. Despite the company's good performance, with significant growth in both revenue and net profit, the market reaction was poor, leading to a 7.07% drop in stock price.
On August 26, Zhitong Finance reported that Ai Kang Medical's performance growth mainly came from overseas markets and smart device sales. The announcement pointed out that the sales growth of overseas and digital orthopedic products drove the improvement in gross margin, but failed to boost the stock price.
On August 26, Ai Kang Medical disclosed its performance through the Hong Kong Stock Exchange, and the decision not to declare dividends may affect investor confidence. The company's choice not to distribute an interim dividend may disappoint some investors and impact stock performance. The recent volatility in Hong Kong stocks has increased, necessitating attention to risks.

Stocks ranked among the top in industry market capitalization

Zhen Jiankang Medical-B fell 1.19%. Based on recent key news:

On August 25, Zhen Jiankang Medical signed a strategic cooperation framework agreement with General Technology Liaoning Pharmaceutical to promote the standardized implementation of tumor minimally invasive interventional technology in the three northeastern provinces. This cooperation is beneficial for enhancing the company's market influence, positively impacting the stock price. Source: Zhitong Finance
On August 26, Zhen Jiankang Medical obtained compliant procurement channels for public hospitals in Liaoning Province through a central enterprise platform, further accelerating the large-scale implementation of tumor minimally invasive surgical robots and specialized solutions, enhancing market confidence. Source: Zhitong Finance
On August 25, Zhen Jiankang Medical issued an announcement emphasizing the strategic depth of its national layout, with tumor minimally invasive diagnosis and treatment solutions taking root in more high-demand areas, leading the market to hold an optimistic view of its future development. Source: Zhitong Finance The medical industry is accelerating technological innovation, and market attention is increasing